NASDAQ:RVNC - Revance Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $29.4250 +0.57 (+1.98 %) (As of 07/22/2018 02:41 PM ET)Previous Close$29.4250Today's Range$28.45 - $29.5052-Week Range$22.05 - $37.45Volume175,958 shsAverage Volume284,172 shsMarket Capitalization$1.08 billionP/E Ratio-7.34Dividend YieldN/ABeta1.33 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California. Receive RVNC News and Ratings via Email Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:RVNC CUSIPN/A Webwww.revance.com Phone510-742-3400 Debt Debt-to-Equity RatioN/A Current Ratio11.89 Quick Ratio11.89 Price-To-Earnings Trailing P/E Ratio-7.34 Forward P/E Ratio-7.60 P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales4,162.51 Cash FlowN/A Price / CashN/A Book Value$7.51 per share Price / Book3.92 Profitability EPS (Most Recent Fiscal Year)($4.01) Net Income$-120,580,000.00 Net Margins-33,807.37% Return on Equity-63.68% Return on Assets-54.86% Miscellaneous Employees134 Outstanding Shares36,780,000Market Cap$1,082.37 Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." How were Revance Therapeutics' earnings last quarter? Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.26. The biopharmaceutical company earned $0.19 million during the quarter, compared to analyst estimates of $0.15 million. Revance Therapeutics had a negative net margin of 33,807.37% and a negative return on equity of 63.68%. View Revance Therapeutics' Earnings History. When is Revance Therapeutics' next earnings date? Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Revance Therapeutics. What price target have analysts set for RVNC? 11 Wall Street analysts have issued 12 month price targets for Revance Therapeutics' stock. Their predictions range from $34.00 to $60.00. On average, they anticipate Revance Therapeutics' stock price to reach $47.20 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price. View Analyst Ratings for Revance Therapeutics. What is the consensus analysts' recommendation for Revance Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Revance Therapeutics stock? Here are some recent quotes from research analysts about Revance Therapeutics stock: 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (7/11/2018) 2. Cantor Fitzgerald analysts commented, "We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $50 and Overweight rating." (5/29/2018) Who are some of Revance Therapeutics' key competitors? Some companies that are related to Revance Therapeutics include Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT) and Blueprint Medicines (BPMC). Who are Revance Therapeutics' key executives? Revance Therapeutics' management team includes the folowing people: Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)Dr. Abhay Joshi, Chief Operating Officer (Age 55)Mr. Todd Erik Zavodnick, Chief Commercial Officer and Pres of Aesthetics & Therapeutics (Age 46)Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications Has Revance Therapeutics been receiving favorable news coverage? News articles about RVNC stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Revance Therapeutics earned a coverage optimism score of 0.07 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.24%), Fred Alger Management Inc. (0.08%), Fox Run Management L.L.C. (0.05%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics. Which major investors are selling Revance Therapeutics stock? RVNC stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Fred Alger Management Inc.. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Insider Buying and Selling for Revance Therapeutics. Which major investors are buying Revance Therapeutics stock? RVNC stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Revance Therapeutics. How do I buy shares of Revance Therapeutics? Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $29.4250. How big of a company is Revance Therapeutics? Revance Therapeutics has a market capitalization of $1.08 billion and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected] MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 234 (Vote Outperform)Underperform Votes: 197 (Vote Underperform)Total Votes: 431MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?